The DTX3 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HeLa cell line, designed for the targeted disruption of the DTX3 gene. This polyclonal pool offers a heterogeneous loss-of-function model suitable for bulk population studies, avoiding clonal artifacts and enabling robust analysis of DTX3-dependent phenotypes in an epithelial cervical adenocarcinoma background.
HeLa cells are an immortalized epithelial cell line derived from cervical adenocarcinoma, extensively used in biomedical research. Their robust proliferation, well-characterized genetics, and responsiveness to Notch pathway modulation make them ideal for studying tumor-associated signaling. This polyclonal knockout population retains parental epithelial morphology and oncogenic context, providing a relevant environment for investigating DTX3 function in cervical cancer.
DTX3 encodes a RING-type E3 ubiquitin ligase that ubiquitinates NOTCH1, mediating its proteasomal degradation and negatively regulating Notch signaling. Activation by ligands DLL1 or JAG1 triggers NOTCH1 cleavage, releasing the intracellular domain (NICD) that induces target genes such as HES1. DTX3 interacts directly with NOTCH1 to control receptor turnover, creating a negative feedback loop that modulates signaling output. In the knockout cells, loss of DTX3 disrupts NOTCH1 degradation, leading to heightened Notch pathway activity and altered downstream transcriptional responses.
In the cervical cancer context of HeLa cells, Notch signaling influences proliferation, survival, and differentiation. By regulating NOTCH1 stability, DTX3 maintains pathway homeostasis. Knockout of DTX3 in this polyclonal pool elevates NOTCH1 levels, potentially hyperactivating HES1 and affecting cell-cycle progression, apoptosis, or epithelial-mesenchymal transition. This model enables dissection of DTX3’s role in cervical cancer cell behavior and Notch-dependent tumorigenesis.
These polyclonal knockout cells are suited for Notch signaling studies, ubiquitin ligase research, and cancer cell phenotyping. Western blotting confirms DTX3 loss and NOTCH1 accumulation; RT-qPCR quantifies HES1 expression; Notch-responsive reporter assays measure pathway activation; flow cytometry detects surface NOTCH1; and proliferation assays assess functional impacts. The polyclonal nature supports population-level analyses and drug screening. For product specifications and experimental guidance, contact Ascent Research.
